Nymox Pharmaceutical Corp (NASDAQ:NYMX) Director Buys $14,040.00 in Stock

Nymox Pharmaceutical Corp (NASDAQ:NYMX) Director James George Robinson bought 9,000 shares of the business’s stock in a transaction on Thursday, June 27th. The shares were acquired at an average cost of $1.56 per share, for a total transaction of $14,040.00. Following the transaction, the director now directly owns 3,453,283 shares in the company, valued at approximately $5,387,121.48. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

James George Robinson also recently made the following trade(s):

  • On Tuesday, July 9th, James George Robinson bought 7,000 shares of Nymox Pharmaceutical stock. The shares were acquired at an average cost of $1.63 per share, for a total transaction of $11,410.00.
  • On Friday, July 5th, James George Robinson bought 9,000 shares of Nymox Pharmaceutical stock. The shares were acquired at an average cost of $1.45 per share, for a total transaction of $13,050.00.
  • On Wednesday, July 3rd, James George Robinson bought 8,000 shares of Nymox Pharmaceutical stock. The shares were acquired at an average cost of $1.54 per share, for a total transaction of $12,320.00.
  • On Monday, July 1st, James George Robinson bought 9,000 shares of Nymox Pharmaceutical stock. The shares were acquired at an average cost of $1.37 per share, for a total transaction of $12,330.00.
  • On Saturday, June 29th, James George Robinson bought 10,000 shares of Nymox Pharmaceutical stock. The shares were acquired at an average cost of $15.16 per share, for a total transaction of $151,600.00.
  • On Tuesday, June 25th, James George Robinson purchased 9,000 shares of Nymox Pharmaceutical stock. The stock was purchased at an average price of $1.73 per share, for a total transaction of $15,570.00.
  • On Thursday, June 20th, James George Robinson purchased 9,000 shares of Nymox Pharmaceutical stock. The stock was purchased at an average price of $1.77 per share, for a total transaction of $15,930.00.
  • On Tuesday, June 18th, James George Robinson purchased 9,000 shares of Nymox Pharmaceutical stock. The stock was purchased at an average price of $1.67 per share, for a total transaction of $15,030.00.
  • On Thursday, June 13th, James George Robinson purchased 8,000 shares of Nymox Pharmaceutical stock. The stock was purchased at an average price of $1.42 per share, for a total transaction of $11,360.00.
  • On Tuesday, June 11th, James George Robinson purchased 9,000 shares of Nymox Pharmaceutical stock. The stock was purchased at an average price of $1.46 per share, for a total transaction of $13,140.00.

Shares of NASDAQ:NYMX traded down $0.03 during trading on Friday, reaching $1.62. The stock had a trading volume of 45,526 shares, compared to its average volume of 278,598. Nymox Pharmaceutical Corp has a one year low of $1.25 and a one year high of $3.42. The company has a debt-to-equity ratio of 0.03, a quick ratio of 8.01 and a current ratio of 8.04. The stock has a 50-day moving average of $1.60.

Nymox Pharmaceutical (NASDAQ:NYMX) last released its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.04) EPS for the quarter. The company had revenue of $0.03 million during the quarter. Nymox Pharmaceutical had a negative return on equity of 175.82% and a negative net margin of 6,101.69%.

Hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its position in Nymox Pharmaceutical by 44.9% in the 4th quarter. Rhumbline Advisers now owns 42,560 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 13,180 shares during the period. Private Advisor Group LLC purchased a new position in Nymox Pharmaceutical in the 4th quarter worth $49,000. Northern Trust Corp raised its position in Nymox Pharmaceutical by 2.2% in the 4th quarter. Northern Trust Corp now owns 277,557 shares of the biopharmaceutical company’s stock worth $363,000 after purchasing an additional 6,026 shares during the period. Brown Advisory Inc. purchased a new position in Nymox Pharmaceutical in the 4th quarter worth $34,000. Finally, Geode Capital Management LLC raised its position in Nymox Pharmaceutical by 10.8% in the 4th quarter. Geode Capital Management LLC now owns 134,021 shares of the biopharmaceutical company’s stock worth $175,000 after purchasing an additional 13,103 shares during the period. Institutional investors own 5.66% of the company’s stock.

Nymox Pharmaceutical Company Profile

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease.

See Also: What are the advantages of the Stochastic Momentum Index?

Insider Buying and Selling by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.